Wave Life Sciences (WVE) Stock Forecast & Price Target

Compare

642 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WVE Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Wave

Life Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WVE Stock 12 Month Forecast

Average Price Target

$18.20

▲(169.63%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $18.20 with a high forecast of $24.00 and a low forecast of $9.00. The average price target represents a 169.63% change from the last price of $6.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","25":"$25","9.25":"$9.25","14.5":"$14.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.25,14.5,19.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.25,7.615384615384615,8.98076923076923,10.346153846153847,11.711538461538462,13.076923076923077,14.442307692307693,15.807692307692308,17.173076923076923,18.53846153846154,19.903846153846153,21.26923076923077,22.634615384615387,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.25,7.1692307692307695,8.088461538461539,9.007692307692308,9.926923076923076,10.846153846153847,11.765384615384615,12.684615384615384,13.603846153846153,14.523076923076923,15.442307692307692,16.36153846153846,17.28076923076923,{"y":18.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.25,6.461538461538462,6.673076923076923,6.884615384615385,7.096153846153846,7.3076923076923075,7.519230769230769,7.730769230769231,7.9423076923076925,8.153846153846153,8.365384615384615,8.576923076923077,8.788461538461538,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.18,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$24.00

Average Price Target$18.20

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

3.70%

Upside

07/03/25

Wave Life Sciences' overall stock score reflects significant financial challenges, including declining revenues and persistent losses. However, positive corporate events, such as progress in clinical trials and a strong cash position, provide a more optimistic outlook. Technical indicators are mixed, and valuation metrics highlight ongoing financial struggles.

Tiago FauthWells Fargo

Wells Fargo

$24

Buy

255.56%

Upside

Reiterated

06/27/25

Wave Life Sciences' WVE-007: Undervalued Potential in Obesity Treatment with Promising Preclinical Results

Andrew FeinH.C. Wainwright

H.C. Wainwright

$22

Buy

225.93%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Wave Life Sciences (NASDAQ: WVE) and MannKind (NASDAQ: MNKD)

Yun ZhongWedbush

Wedbush

$18

Buy

166.67%

Upside

Reiterated

06/23/25

Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Lineage Therap (LCTX)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$10

Buy

48.15%

Upside

Reiterated

06/22/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Perspective Therapeutics (NYSE MKT: CATX) and PTC Therapeutics (NASDAQ: PTCT)

Martin AusterRaymond James

Raymond James

$14

Buy

107.41%

Upside

Initiated

06/10/25

Wave Life Sciences (WVE) Initiated with a Buy at Raymond James

Salim SyedMizuho Securities

Mizuho Securities

$22

Buy

225.93%

Upside

Reiterated

06/09/25

Analysts Offer Insights on Healthcare Companies: Natera (NASDAQ: NTRA) and Wave Life Sciences (NASDAQ: WVE)

Catherine NovackJonesTrading

JonesTrading

$20

Buy

196.30%

Upside

Reiterated

05/16/25

We are at ASGCT this week and caught Wave's oral sessions on their siRNA and RNA editing programs.

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/09/25

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Joseph SchwartzLeerink Partners

Leerink Partners

$24

Buy

255.56%

Upside

Reiterated

05/08/25

Wave Life Sciences: Strategic Advancements and Promising Developments Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$10→$9

Hold

33.33%

Upside

Reiterated

05/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alpha Teknova (NASDAQ: TKNO), Definitive Healthcare Corp (NASDAQ: DH) and Wave Life Sciences (NASDAQ: WVE)

Madison ElsaadiB.Riley Financial

B.Riley Financial

$22→$19

Buy

181.48%

Upside

Reiterated

04/10/25

Wave Life Sciences price target lowered to $19 from $22 at B. RileyWave Life Sciences price target lowered to $19 from $22 at B. Riley

Roger SongJefferies

Jefferies

$26

Buy

285.19%

Upside

Reiterated

03/26/25

Jefferies reiterates Buy Rating on WAVE Life Sciences (WVE)Jefferies analyst Roger Song reiterated a Buy rating and $26.00 price target on WAVE Life Sciences (NASDAQ: WVE).

Eric JosephJ.P. Morgan

J.P. Morgan

$20→$21

Buy

211.11%

Upside

Reiterated

03/04/25

WAVE Life Sciences (WVE) PT Raised to $21 at JPMorganJPMorgan analyst Eric Joseph raised the price target on WAVE Life Sciences (NASDAQ: WVE) to $21.00 (from $20.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

3.70%

Upside

07/03/25

Tiago FauthWells Fargo

Wells Fargo

$24

Buy

255.56%

Upside

Reiterated

06/27/25

Wave Life Sciences' WVE-007: Undervalued Potential in Obesity Treatment with Promising Preclinical Results

Andrew FeinH.C. Wainwright

H.C. Wainwright

$22

Buy

225.93%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Wave Life Sciences (NASDAQ: WVE) and MannKind (NASDAQ: MNKD)

Yun ZhongWedbush

Wedbush

$18

Buy

166.67%

Upside

Reiterated

06/23/25

Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Lineage Therap (LCTX)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$10

Buy

48.15%

Upside

Reiterated

06/22/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Perspective Therapeutics (NYSE MKT: CATX) and PTC Therapeutics (NASDAQ: PTCT)

Martin AusterRaymond James

Raymond James

$14

Buy

107.41%

Upside

Initiated

06/10/25

Wave Life Sciences (WVE) Initiated with a Buy at Raymond James

Salim SyedMizuho Securities

Mizuho Securities

$22

Buy

225.93%

Upside

Reiterated

06/09/25

Analysts Offer Insights on Healthcare Companies: Natera (NASDAQ: NTRA) and Wave Life Sciences (NASDAQ: WVE)

Catherine NovackJonesTrading

JonesTrading

$20

Buy

196.30%

Upside

Reiterated

05/16/25

We are at ASGCT this week and caught Wave's oral sessions on their siRNA and RNA editing programs.

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/09/25

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Joseph SchwartzLeerink Partners

Leerink Partners

$24

Buy

255.56%

Upside

Reiterated

05/08/25

Wave Life Sciences: Strategic Advancements and Promising Developments Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$10→$9

Hold

33.33%

Upside

Reiterated

05/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alpha Teknova (NASDAQ: TKNO), Definitive Healthcare Corp (NASDAQ: DH) and Wave Life Sciences (NASDAQ: WVE)

Madison ElsaadiB.Riley Financial

B.Riley Financial

$22→$19

Buy

181.48%

Upside

Reiterated

04/10/25

Wave Life Sciences price target lowered to $19 from $22 at B. RileyWave Life Sciences price target lowered to $19 from $22 at B. Riley

Roger SongJefferies

Jefferies

$26

Buy

285.19%

Upside

Reiterated

03/26/25

Jefferies reiterates Buy Rating on WAVE Life Sciences (WVE)Jefferies analyst Roger Song reiterated a Buy rating and $26.00 price target on WAVE Life Sciences (NASDAQ: WVE).

Eric JosephJ.P. Morgan

J.P. Morgan

$20→$21

Buy

211.11%

Upside

Reiterated

03/04/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wave Life Sciences

1 Month

xxx

Success Rate

7/15 ratings generated profit

Average Return

+5.40%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +5.40% per trade.

3 Months

xxx

Success Rate

6/15 ratings generated profit

Average Return

+16.99%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +16.99% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

10/15 ratings generated profit

Average Return

+24.85%

reiterated a buy rating 11 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.85% per trade.

2 Years

xxx

Success Rate

9/15 ratings generated profit

Average Return

+19.35%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +19.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WVE Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WVE has received 17 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. WVE average Analyst price target in the past 3 months is 18.20.

Each month's total comprises the sum of three months' worth of ratings.

WVE Financial Forecast

WVE Earnings Forecast

Next quarter’s earnings estimate for WVE is -$0.27 with a range of -$0.37 to -$0.10. The previous quarter’s EPS was -$0.29. WVE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year WVE has Preformed in-line its overall industry.

WVE Sales Forecast

Next quarter’s sales forecast for WVE is $14.31M with a range of $0.00 to $36.99M. The previous quarter’s sales results were $9.18M. WVE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year WVE has Preformed in-line its overall industry.

WVE Stock Forecast FAQ

What is WVE’s average 12-month price target, according to analysts?

Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 18.20.

What is WVE’s upside potential, based on the analysts’ average price target?

Wave Life Sciences has 169.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WVE a Buy, Sell or Hold?

Wave Life Sciences has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Wave Life Sciences’s price target?

The average price target for Wave Life Sciences is 18.20. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $24.00 ,the lowest forecast is $9.00. The average price target represents 169.63% Increase from the current price of $6.75.

What do analysts say about Wave Life Sciences?

Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of WVE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Wave Life Sciences (WVE) Stock Forecast & Price Target

WVE Analyst Ratings

WVE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wave Life Sciences

WVE Analyst Recommendation Trends

WVE Financial Forecast

WVE Earnings Forecast

WVE Sales Forecast

WVE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts